Stockscreener 앱 받기
1.06
3.65%
-0.04
Bioxcel Therapeutics Inc 주식(BTAI)의 최신 뉴스
Price to sales forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
BTAI Stock Gained 5% TodayWhat's The Latest On Its Opioid Withdrawal Treatment? - Stocktwits
Price to sales forward of BioXcel Therapeutics, Inc. – MUN:BX20 - TradingView
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell 3000E Growth Benchmark - marketscreener.com
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell 3000E Index - marketscreener.com
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell Microcap Index - marketscreener.com
BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
Price to earnings forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
Enterprise value to revenue forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
Enterprise value to EBITDA forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
BioXcel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Yocca Frank - Moomoo
BioXcel Therapeutics, Inc. Actuals & Estimates (FWB:BX20) - TradingView
BTAI Should I Buy - Intellectia AI
BioXcel Therapeutics, Inc. Actuals & Estimates (NASDAQ:BTAI) - TradingView
BioXcel Therapeutics, Inc. Actuals & Estimates (LSX:A40YSR) - TradingView
BTAI Forecast — Price Target — Prediction for 2027 - TradingView
BioXcel Therapeutics Inc. (BTAI) Q1 2026 Earnings: Surprise EPS Beat Drives Stock RallyEarnings Per Share - dars.gov.et
BioXcel Therapeutics Q1 2026 Earnings: EPS Beat Driven by Cost Controls Despite No RevenuePost-Announcement Reaction - Město Břeclav
BioXcel Therapeutics Inc (BTAI) Valuation: PE, PB & Fair Value Analysis - TradingKey
BTAI Q1 2026 Earnings: EPS Beat Amid No Revenue; Stock Edges UpEarnings Growth Analysis - dars.gov.et
BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
BioXcel Therapeutics (NASDAQ: BTAI) officer converts RSUs into Common Stock - Stock Titan
BioXcel (BTAI) CEO exercises 219 RSUs and reports major indirect stakes - Stock Titan
BioXcel Therapeutics (BTAI) CSO converts 35 RSUs, now holds 26,210 shares - Stock Titan
BioXcel (BTAI) CFO gains 35 shares as 212 RSUs remain - Stock Titan
BioXcel Therapeutics Inc (BTAI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioXcel Therapeutics Inc (BTAI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioXcel Therapeutics Inc (BTAI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioXcel Therapeutics Inc (BTAI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioXcel Therapeutics Inc (BTAI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioXcel Therapeutics Inc (BTAI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioXcel Therapeutics Inc (BTAI) Institutional Confidence - TradingKey
BioXcel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Steinhart Richard I - Moomoo
Attention BioXcel Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed against BioXcel Therapeutics, Inc. (BTAI) and Encourages Investors to Contact the Firm - TMX Newsfile
What makes BioXcel Therapeutics (BTAI) a new buy stock - MSN
BioXcel Deadline Alert - TMX Newsfile
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock - Yahoo Finance
BioXcel Shareholder Action Reminder - TMX Newsfile
BTAI Technical Analysis & Stock Price Forecast - Intellectia AI
BioXcel presents data on at-home agitation treatment trial By Investing.com - Investing.com India
BioXcel Therapeutics Presents New Data from Serenity At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia - marketscreener.com
BioXcel presents data on at-home agitation treatment trial - Investing.com
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting - The Manila Times
BioXcel Therapeutics Presents New Data from SERENITY - GlobeNewswire
At-home bipolar and schizophrenia agitation drug cuts symptoms in Phase 3 - Stock Titan
BioXcel Therapeutics | 424B5: Prospectus - Moomoo
BioXcel Therapeutics Company Profile & Introduction - Moomoo
BTAIBioXcel Therapeutics Inc Stock Price and Quote - Finviz
BioXcel Therapeutics CEO Mehta sells $21,108 in company stock By Investing.com - Investing.com Nigeria
BioXcel Therapeutics chief legal officer sells $7,111 in stock By Investing.com - Investing.com Nigeria
BioXcel CFO Richard Steinhart sells $7,426 of stock By Investing.com - Investing.com India
BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock By Investing.com - Investing.com Nigeria
0.71%
1.43%
자본화:
|
볼륨(24시간):